1 |
Kennedy RM. 2005. Expanded-bed adsorption chromatography. Current Protocols in Protein Science Chapter 8:Unit 8.8.
|
2 |
KFDA (Korean Ministry of Food and Drug Safety). 2015. Partial amendment official announcement about toxicity test for Drug. KFDA, Cheongju, Korea.
|
3 |
Lee YS, Suh CW, Park SK, Lee EK. 2003. Purification of soluble human epidermal growth factor (hEGF) from recombinant Escherichia coli culture broth by using expanded-bed adsorption chromatography. Biotechnology and Applied Biochemistry 38:9-13.
DOI
|
4 |
Matsui M, Oshima M, Oshima H, Takaku K, Maruyama T, Yodoi J, Taketo MM. 1996. Early embryonic lethality caused by targeted disruption of the mouse thioredoxin gene. Developmental Biology 178:179-185.
DOI
|
5 |
Meng L, Wong JH, Feldman LJ, Lemaux PG, Buchanan BB. 2010. A membrane-associated thioredoxin required for plant growth moves from cell to cell, suggestive of a role in intercellular communication. Proceedings of the National Academy of Sciences of the United States of America 107:3900-3905.
DOI
|
6 |
Nordberg J, Arner ES. 2001. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radical Biology and Medicine 31:1287-1312.
|
7 |
OECD (Organisation for Economic Co-operation and Development). 2002a. Test No. 420: Acute oral toxicity-fixed dose procedure, OECD guidelines for the testing of chemicals, section 4. OECD, Paris, France.
|
8 |
OECD (Organisation for Economic Co-operation and Development). 2002b. Test No. 423: Acute oral toxicity-acute toxic class method. OECD, Paris, France.
|
9 |
Oh SD, Min SK, Kim JK, Park JH, Kim CG, Park SY. 2020. Risk assessment and evaluation of epidermal growth factor (EGF) transgenic soybean: Responses of Cyprinus carpio fed on EGF transgenic soybean. Korean Journal of Agricultural Science 47:815-827.
|
10 |
Ono R, Masaki T, Dien S, Yu X, Fukunaga A, Yodoi J, Nishigori C. 2012. Suppressive effect of recombinant human thioredoxin on ultraviolet light-induced inflammation and apoptosis in murine skin. The Journal of Dermatology 39:843-851.
DOI
|
11 |
Sharma K, Babu PVC, Sasidhar P, Srinivas VK, Mohan VK, Krishna E. 2008. Recombinant human epidermal growth factor inclusion body solubilization and refolding at large scale using expanded-bed adsorption chromatography from Escherichia coli. Protein Expression and Purification 60:7-14.
DOI
|
12 |
Tian H, Matsuo Y, Fukunaga A, Ono R, Nishigori C, Yodoi J. 2013. Thioredoxin ameliorates cutaneous inflammation by regulating the epithelial production and release of pro-inflammatory cytokines. Frontiers in Immunology 4:269.
|
13 |
Wilkins MR, Gasteiger E, Bairoch A, Sanchez JC, Williams KL, Appel RD, Hochstrasser DF. 1999. Protein identification and analysis tools in the ExPASy server. Methods in Molecular Biology 112:531-552.
|
14 |
Yodoi J, Matsuo Y, Tian H, Masutani H, Inamoto T. 2017. Anti-inflammatory thioredoxin family proteins for medicare, healthcare and aging care. Nutrients 9:1081.
|
15 |
Hardwicke J, Schmaljohann D, Boyce D, Thomas D. 2008. Epidermal growth factor therapy and wound healing-past, present and future perspectives. The Surgeon 6:172-177.
DOI
|
16 |
Carpenter G, Cohen S. 1990. Epidermal growth factor. Journal of Biological Chemistry 265:7709-7712.
DOI
|
17 |
Fukunaga A, Horikawa T, Ogura K, Taguchi K, Yu X, Funasaka Y, Takeda M, Nakamura H, Yodoi J, Nishigori C. 2009. Thioredoxin suppresses the contact hypersensitivity response by inhibiting leukocyte recruitment during the elicitation phase. Antioxidants and Redox Signaling 11:1227-1235.
DOI
|